NCT04508660已完成1 期
Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 3
- 主要终点
- Investigator's Global Assessment of Redness (IGA-R)
研究概览
简要总结
Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness
详细描述
This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce facial redness typically associated with rosacea. Approximately 25 subjects will be enrolled.
Subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (BL, W1, W2, W4).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline and practice a reliable method of contraception throughout the study.
- •Facial redness associated with rosacea.
- •Facial redness (IGA-R) score of 2 or 3 (i.e., mild or moderate).
- •Absence of any skin conditions that could interfere with the visual erythema assessments.
- •Willing to forego any other topical or non-topical treatment on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer).
- •Willing to use the provided skincare regimen (e.g., face wash and moisturizer) over the duration of the study.
- •Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures being performed.
排除标准
- •Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Products (i.e., essential oils, fragrance, choline, phosphatidylcholine, etc.).
- •Any transient flushing syndrome.
- •History of basal cell carcinoma within 6 months of Visit
- •History or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
- •Diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans at Baseline.
- •Blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist.
- •Uncontrolled systemic disease.
- •Foreseen unprotected and intense/excessive UV exposure during the course of the study.
- •Use of any of the following concomitant medications/procedures:
- •Cosmetic and/or OTC products for redness reduction and/or skin clearing
- •Topical medications for rosacea
- •Systemic antibiotics or corticosteroids
- •Topical antibiotics, corticosteroids, or antiparasitic agents
- •Intense/excessive ultraviolet (UV) radiation
- •Phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion
- •Exposure to any other investigational drug/device within 30 days prior to study entry.
研究组 & 干预措施
Subjects with facial redness
Experimental
Topical application twice daily for 4 weeks
干预措施: CGB-400 (Drug)
结局指标
主要结局
Investigator's Global Assessment of Redness (IGA-R)
时间窗: 4 weeks
5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness)
次要结局
- Patient Global Assessment(Week 1, Week 2, Week 4)
- Investigator's Global Assessment of Redness (IGA-R)(Day 0, Week 1, Week 2)
- Bumps/Blemishes Count(Day 0, Week 1, Week 2, Week 4)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
CGB-400 for the Reduction of Facial Redness and Bumps and BlemishesRosaceaNCT04508205CAGE Bio Inc.27
已完成
2 期
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of RosaceaRosaceaNCT04886739CAGE Bio Inc.78
Unknown
不适用
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal InfectionTinea UnguiumFungal InfectionOnychomycosisNCT05202366CAGE Bio Inc.15
已完成
不适用
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced ErythemaErythemaSun Damaged SkinSkin InflammationNCT05300542Amazentis SA22
已完成
3 期
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With RosaceaRosaceaNCT01355471Galderma R&D293